LifeStance Health Group research snapshot
LifeStance Health Group (LFST) trades at $10.70 as of July 10, 2026, with a market capitalization of $4.15 billion. The AI analysis rates LFST a Moderate Buy with a score of 6.2/10. The company is in an uptrend after recovering from its March 2026 lows near $3.74 to recent 52-week highs above $11.60. Business fundamentals are improving steadily: revenue grew 21% year-over-year in Q1 2026, the company achieved its fourth consecutive quarter of positive net income, and operating margins expanded from negative territory to 5.5%. Valuation remains elevated at 178x trailing P/E, reflecting market expectations for continued profitability improvement in the outpatient behavioral health space. This analysis is for informational purposes only and does not constitute investment advice.
Current price
$10.70
Market cap
$4.15B
AI score
6.2
Rating
Moderate Buy
Trend status
Uptrend
Data cutoff (updated weekly)
2026-07-12
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business Quality | Outpatient behavioral health is a structurally growing market. LFST operates a scaled clinic network with in-network insurance contracts. | Medium |
| Moat | Moderate: Local clinic density, insurance panel relationships, and brand recognition create some barriers. Low switching costs for individual patients. | Medium |
| Management | Management has executed well on revenue growth and margin improvement trajectory. Recent insider selling of $64M is a concern. | Low |
| Financial Trend | Strong improvement: from net loss to positive net income over the past four quarters. Revenue growing 21% YoY with improving operating leverage. | High |
| Valuation | Expensive on trailing earnings (178x P/E). More reasonable on forward P/E (~89x) and P/S (2.9x). The market is pricing in aggressive margin expansion. | Medium |
| Technical Trend | Strong uptrend. Price has risen 186% from the 52-week low of $3.74. Recently pulled back from the 52-week high of $11.62. | High |
| Risk Level | Elevated. High valuation, insider selling, regulatory risks in behavioral health, and dependence on clinician staffing. | Medium |
| AI Confidence | Medium. Financial data is reliable, but the investment thesis depends on execution in a competitive labor market for clinicians. | Medium |
| Investment Certainty | Low. The valuation multiple leaves little room for error. Sustainable competitive advantage is not yet proven. | Medium |
LFST AI stock forecast
LFST price targets span $8.00 to $13.00 per analysts surveyed. The AI base case is $10.90 (roughly flat to current) over 3 years, assuming 20% annual EPS growth and a 30x P/E multiple. Bull case reaches $18.50 if the company sustains 30% growth and the market re-rates to 40x. Bear case falls to $5.60 if margin expansion stalls and the market re-rates to 20x.
$14.00 - $18.50
Revenue growth sustains above 25% YoY, operating margins exceed 10% within 2 years, clinicians remain available at manageable wage inflation, and the market assigns a 35-40x forward P/E in recognition of the scalable platform.
$9.00 - $11.00
Revenue grows 18-22% annually, margins gradually improve to 8-10% over 3 years, analyst consensus is broadly met, and the P/E settles at 25-30x forward earnings as the company proves recurring profitability.
$5.00 - $8.00
Clinician shortage worsens, wage costs accelerate, payer reimbursement tightens, revenue growth decelerates below 15%, or the company fails to sustain positive net income.
LFST AI technical analysis
LFST is in a strong uptrend after bouncing from $3.74 (52-week low) to a recent high of $11.62. The stock is pulling back from resistance near $11.60. Volume has been above average on up-moves. The 50-day moving average near $7.50 provided support in May 2026. Momentum indicators show short-term weakness after the recent pullback, but the medium-term trend remains intact.
| Level | Value | Why it matters |
|---|---|---|
| Resistance (52-week high) | $11.62 | July 2026 high. Break above this level targets $13.00. |
| Resistance (Analyst high) | $13.00 | UBS price target. Next resistance zone if $11.62 clears. |
| Support (Recent) | $10.50 | Near the 10-day moving average after the pullback. |
| Support (50-day MA) | $7.50 | Provided support during May 2026 pullback. |
| Support (52-week low) | $3.74 | March 2026 low. Represents the market floor during a distressed period. |
| 50-Day Moving Average | $7.50 | Rising, confirming the medium-term uptrend. |
| 200-Day Moving Average | $5.90 | Well below current price; long-term trend is bullish. |
| RSI (14-day) | 45 | Near neutral after pullback from overbought. Room to move higher. |
| Average Volume | 3.95M shares | Elevated volume during the uptrend indicates strong participation. |
| Beta | 1.12 | Slightly more volatile than the overall market. |
LFST AI trading strategy
LFST is in a confirmed uptrend but extended after a 186% rally from its low. A pullback toward moving average support levels may offer lower-risk entry points. Position sizing should account for the elevated P/E multiple, which makes LFST susceptible to multiple compression if growth disappoints.
Buy on pullbacks to the 50-day MA ($7.50) or the rising trendline from the March 2026 low. Add to position if volume confirms the bounce and RSI holds above 40.
Place a stop-loss below the most recent swing low (approximately $9.80 on the current pullback) or below $7.00 for a wider stop. Reduce position size if price falls below the 50-day MA.
If LFST clears the $11.62 52-week high on above-average volume, it may run toward the $13.00 analyst target. Wait for a weekly close above $11.62 before entering.
Set a stop at $10.50 (recent support). Trail the stop 8-10% below price as the position advances. Take partial profits at $13.00.
If LFST extends above $13.00 without fundamental catalysts, it may be overextended. A short-term mean-reversion trade targets a move back toward $11.00-11.50.
Aggressive strategy not suitable for most investors. Tight stop above $14.00. This is a counter-trend trade with defined risk.
Investment research summary
LifeStance Health operates a national network of outpatient behavioral health clinics. Patients (and their insurance plans) pay for therapy, psychiatry, TMS, and ketamine treatments delivered in-person or via telehealth. The business grows by opening new clinics and acquiring existing practices, then improving their payer mix and utilization.
LFSTs moat is moderate and still being built. Local market density creates some competitive advantage in contracting with insurance plans. The brand is gaining recognition but lacks the switching costs of a platform business. Patients can easily switch providers, though LFSTs insurance network participation creates stickiness for in-network patients. The company has not yet demonstrated pricing power.
The thesis fails if: (1) clinician wages rise faster than reimbursement rates, (2) insurance companies reduce behavioral health reimbursement, (3) LFST cannot scale quality clinicians fast enough, (4) regulatory changes increase compliance costs, or (5) a recession reduces discretionary utilization of behavioral health services. The biggest risk is that LFST remains perpetually unprofitable at scale.
Management has guided the company from losses to GAAP profitability in four quarters, which is commendable. The $100M buyback authorized in February 2026 signals confidence. However, recent insider selling of $64M in stock over the past three months warrants attention, particularly from director Robert Bessler who sold 894,337 shares in July 2026.
Behavioral health is in a secular growth phase driven by rising mental health awareness, reduced stigma, and expanded insurance coverage. The U.S. faces a clinician shortage that simultaneously creates demand (underserved market) and a supply constraint (higher wages). LFST is positioned to benefit from consolidation in a fragmented industry.
At $10.70 and $0.06 TTM EPS, LFST trades at 178x earnings. Using forward estimates of $0.21 EPS, the forward P/E is 51x. A three-scenario DCF-style projection: Bull (30% growth, 40x P/E) = $18.50 (+73%), Base (20% growth, 30x P/E) = $10.90 (+2%), Bear (10% growth, 20x P/E) = $5.60 (-48%). The current price offers little margin of safety in the base case and significant downside in the bear case.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current Price | $10.70 | Google Finance | 2026-07-12 |
| Market Capitalization | $4.15B | MarketBeat | 2026-07-12 |
| Shares Outstanding | 387.83M | Google Finance | 2026-07-12 |
| Trailing P/E | 178.33x | MarketBeat | 2026-07-12 |
| Forward P/E | 89.17x | MarketBeat | 2026-07-12 |
| Price/Sales (TTM) | 2.91x | MarketBeat | 2026-07-12 |
| Revenue (TTM) | $1.49B | Google Finance (4Q sum) | 2026-07-12 |
| Net Income (TTM) | $23.2M | Google Finance (4Q sum) | 2026-07-12 |
| Q1 2026 Revenue | $403.48M | Google Finance | 2026-07-12 |
| Q1 2026 EPS | $0.07 (beat by $0.01) | MarketBeat | 2026-07-12 |
| 52-Week Range | $3.74 - $11.62 | Google Finance | 2026-07-12 |
This LFST stock analysis is an AI-generated informational tool based on publicly available data as of July 12, 2026. It is not investment advice, a recommendation to buy or sell securities, or a solicitation of any kind. Forecast scenarios are hypothetical estimates based on current data, analyst consensus, and AI modeling assumptions. They may be materially wrong. Past performance does not guarantee future results. Always conduct your own research and consult a licensed financial advisor before making investment decisions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
